Please login to the form below

Not currently logged in
Email:
Password:

radium-223 dichloride

This page shows the latest radium-223 dichloride news and features for those working in and with pharma, biotech and healthcare.

Japanese approvals for GSK, AZ and Bayer

Japanese approvals for GSK, AZ and Bayer

Finally, Bayer has won Japanese approval for Xofigo (radium-223 dichloride, radium-223), its radiopharmaceutical drug for the treatment of patients with castration-resistant prostate cancer and bone metastases.

Latest news

  • Price cut keeps Kadcyla on CDF Price cut keeps Kadcyla on CDF

    Bayer's Xofigo (radium-223 dichloride) for castration-resistant prostate cancer with bone metastases remains under appeal.

  • Eylea growth closes the gap with Lucentis Eylea growth closes the gap with Lucentis

    Combined sales of Bayer's five growth products - Eylea, pulmonary hypertension drug Adempas (riociguat), anticoagulant Xarelto (rivaroxaban) and cancer therapies Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) - came in at

  • Bayer's Eylea cleared for wider use in Europe Bayer's Eylea cleared for wider use in Europe

    For the full year, revenues were up 5% to 42.2bn. The company's five most recently launched drugs - Eylea; anticoagulant Xarelto (rivaroxaban); cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra ... 223 dichloride); and pulmonary hypertension

  • Personalised cancer medicines showcased in BBC investigation Personalised cancer medicines showcased in BBC investigation

    Astellas and Medivation's advanced prostate cancer drug Xtandi (enzalutamide) was highlighted being used with Bayer's Xofigo (Radium Ra 223 Dichloride) for an elderly patient with late-stage prostate cancer

  • Bayer CEO Dekkers points to 'outstanding' pharma growth Bayer CEO Dekkers points to 'outstanding' pharma growth

    Prostate cancer drug Xofigo (radium-223 dichloride) also built momentum, bringing in 49m in the quarter, although Bayer will want to see a sizeable uptick in sales to offset the

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics